| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Willem de Vos | Q8003634 |
| Paul Enck | Q7150501 | ||
| Anne Salonen | Q45931194 | ||
| Robin Spiller | Q42693271 | ||
| Jeroen Raes | Q50285889 | ||
| Kurt Hanevik | Q56750259 | ||
| Jonna Jalanka | Q57013504 | ||
| Elena Philippou | Q58120142 | ||
| John Penders | Q60974490 | ||
| Daisy M A E Jonkers | Q90645876 | ||
| Gerard Clarke | Q37371783 | ||
| P2093 | author name string | Fuad A Iraqi | |
| Mirjana Rajilić-Stojanović | |||
| Natasa Golic | |||
| P2860 | cites work | Development of the human infant intestinal microbiota | Q21003936 |
| Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes | Q21261902 | ||
| Human gut microbiome viewed across age and geography | Q24602950 | ||
| Linking long-term dietary patterns with gut microbial enterotypes | Q24609914 | ||
| Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa | Q24622141 | ||
| Intestinal microbiota in functional bowel disorders: a Rome foundation report | Q24631357 | ||
| Brain-gut microbiome interactions and functional bowel disorders | Q27014531 | ||
| Methanogens, methane and gastrointestinal motility | Q27693339 | ||
| Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome | Q28238388 | ||
| Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis | Q28244815 | ||
| Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management | Q28265447 | ||
| Mom knows best: the universality of maternal microbial transmission | Q28681765 | ||
| Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns | Q29547261 | ||
| Bacterial community variation in human body habitats across space and time | Q29547432 | ||
| Diet rapidly and reproducibly alters the human gut microbiome | Q29547454 | ||
| Factors influencing the composition of the intestinal microbiota in early infancy | Q29614578 | ||
| Succession of microbial consortia in the developing infant gut microbiome | Q29615811 | ||
| Effects of lactulose and polyethylene glycol on colonic transit | Q45250883 | ||
| Phylogenetic analysis of dysbiosis in ulcerative colitis during remission | Q45367129 | ||
| Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life | Q45840782 | ||
| Intake of whole-grain and fiber-rich rye bread versus refined wheat bread does not differentiate intestinal microbiota composition in Finnish adults with metabolic syndrome. | Q45931143 | ||
| The effects of butyrate enemas on visceral perception in healthy volunteers. | Q46002158 | ||
| Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome. | Q46145035 | ||
| Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity | Q46808316 | ||
| Intestinal microbiota during early life - impact on health and disease. | Q46883640 | ||
| Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics | Q47388708 | ||
| Lactose intolerance in irritable bowel syndrome patients with diarrhoea: the roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity | Q47948046 | ||
| Hydrogen sulfide is a novel prosecretory neuromodulator in the Guinea-pig and human colon. | Q40209080 | ||
| Rapid isolation of Yersinia spp. from feces | Q40223326 | ||
| The fecal microbial population in the irritable bowel syndrome. | Q41625029 | ||
| Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran | Q42032134 | ||
| Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome | Q43244921 | ||
| Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study | Q43333301 | ||
| Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). | Q43342445 | ||
| Food-related gastrointestinal symptoms in the irritable bowel syndrome | Q43539583 | ||
| An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. | Q48516420 | ||
| Does meal ingestion enhance sensitivity of visceroperception assessment in irritable bowel syndrome? | Q51365874 | ||
| Health-related quality of life in patients attending a gastroenterology outpatient clinic: functional disorders versus organic diseases. | Q53258044 | ||
| Long-term monitoring of the human intestinal microbiota composition. | Q54084125 | ||
| A serpin from the gut bacterium Bifidobacterium longum inhibits eukaryotic elastase-like serine proteases. | Q54466580 | ||
| Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects. | Q54677345 | ||
| Methanogens in Human Health and Disease | Q56048193 | ||
| Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood | Q56968869 | ||
| Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR | Q63242386 | ||
| Are adverse food reactions linked to irritable bowel syndrome? | Q64937739 | ||
| A critical evaluation of clinical trials in adverse reactions to foods in adults | Q69549984 | ||
| Contribution of the microflora to proteolysis in the human large intestine | Q70381662 | ||
| Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation | Q71723152 | ||
| A population study of food intolerance | Q72677451 | ||
| Dissimilatory amino Acid metabolism in human colonic bacteria | Q80057162 | ||
| Use of broad-spectrum antibiotics and the development of irritable bowel syndrome | Q83990215 | ||
| Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome | Q84705462 | ||
| Nutrient intake in patients with irritable bowel syndrome compared with the general population | Q84909219 | ||
| Assessment of bacterial diversity in breast milk using culture-dependent and culture-independent approaches | Q86422054 | ||
| Diets that differ in their FODMAP content alter the colonic luminal microenvironment | Q87389891 | ||
| IgG and IgG4 antibodies in subjects with irritable bowel syndrome: a case control study in the general population | Q34484272 | ||
| The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota | Q34596449 | ||
| Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome | Q34635154 | ||
| Review article: the role of butyrate on colonic function. | Q34708137 | ||
| Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome | Q34867735 | ||
| Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome | Q35059823 | ||
| Impact of diet on human intestinal microbiota and health. | Q35081617 | ||
| Gut microbiome of the Hadza hunter-gatherers | Q35148961 | ||
| Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men | Q35157012 | ||
| The placenta harbors a unique microbiome | Q35171983 | ||
| Microbiota and neurodevelopmental windows: implications for brain disorders | Q35193501 | ||
| Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome | Q35362266 | ||
| Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota | Q35409022 | ||
| Intestinal microecology and quality of life in irritable bowel syndrome patients | Q36065979 | ||
| Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. | Q36160305 | ||
| Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months | Q36698632 | ||
| Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients | Q37234016 | ||
| Bile acids as regulatory molecules | Q37297846 | ||
| Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis | Q37443513 | ||
| Fasting and postprandial volumes of the undisturbed colon: normal values and changes in diarrhea-predominant irritable bowel syndrome measured using serial MRI. | Q37715649 | ||
| Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit | Q37716041 | ||
| Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives | Q37779675 | ||
| The role of eosinophils and mast cells in intestinal functional disease. | Q37873352 | ||
| Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis | Q37994513 | ||
| Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome | Q38029994 | ||
| Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. | Q38052154 | ||
| Dietary lipids and functional gastrointestinal disorders | Q38097270 | ||
| Function of the microbiota | Q38114541 | ||
| Non-celiac wheat sensitivity as an allergic condition: personal experience and narrative review | Q38156292 | ||
| Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. | Q39208620 | ||
| Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence | Q39320245 | ||
| Functional bowel disorders | Q29620328 | ||
| Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States | Q30422767 | ||
| Reclassification of Eubacterium formicigenerans Holdeman and Moore 1974 as Dorea formicigenerans gen. nov., comb. nov., and description of Dorea longicatena sp. nov., isolated from human faeces | Q30684802 | ||
| Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI | Q30697372 | ||
| Mechanisms and efficacy of dietary FODMAP restriction in IBS. | Q30738587 | ||
| British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults | Q31054269 | ||
| Dynamics and associations of microbial community types across the human body | Q31158807 | ||
| Reclassification of Clostridium coccoides, Ruminococcus hansenii, Ruminococcus hydrogenotrophicus, Ruminococcus luti, Ruminococcus productus and Ruminococcus schinkii as Blautia coccoides gen. nov., comb. nov., Blautia hansenii comb. nov., Blautia h | Q31168195 | ||
| Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria | Q33238568 | ||
| The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects | Q33290848 | ||
| Diversity of the human gastrointestinal tract microbiota revisited. | Q33293596 | ||
| Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome | Q33447288 | ||
| The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. | Q33458071 | ||
| Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet | Q33458326 | ||
| Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome | Q33481455 | ||
| Abnormal colonic fermentation in irritable bowel syndrome | Q33487908 | ||
| Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers | Q33518947 | ||
| Consumption of human milk oligosaccharides by gut-related microbes | Q33556097 | ||
| Irritable bowel syndrome: the role of food in pathogenesis and management | Q33582170 | ||
| Dominant and diet-responsive groups of bacteria within the human colonic microbiota | Q33649520 | ||
| Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. | Q33718086 | ||
| Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome | Q33779218 | ||
| Dietary intakes in people with irritable bowel syndrome. | Q33811317 | ||
| Intestinal microbiota in pathophysiology and management of irritable bowel syndrome | Q33958729 | ||
| No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. | Q34036599 | ||
| Dietary intervention impact on gut microbial gene richness | Q34037982 | ||
| A diet low in FODMAPs reduces symptoms of irritable bowel syndrome | Q34038352 | ||
| Hydrogen sulfide and colonic epithelial metabolism: implications for ulcerative colitis | Q34087070 | ||
| Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome | Q34155038 | ||
| Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial | Q34158501 | ||
| Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. | Q34284553 | ||
| The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis | Q34431190 | ||
| Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences | Q34481544 | ||
| Diet and functional gastrointestinal disorders: a population-based case-control study | Q34481783 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human digestive system | Q9649 |
| irritable bowel syndrome | Q838966 | ||
| environment | Q2249676 | ||
| physiological phenomenon | Q66615932 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 278-87 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? | |
| P478 | volume | 110 |
| Q59303894 | A low FODMAP diet is associated with changes in the microbiota and reduction in breath hydrogen but not colonic volume in healthy subjects |
| Q55394076 | Altered Intestinal Microbiota with Increased Abundance of Prevotella Is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome. |
| Q36318355 | Altered gut microbiome in a mouse model of Gulf War Illness causes neuroinflammation and intestinal injury via leaky gut and TLR4 activation |
| Q61398217 | Aluminum Ingestion Promotes Colorectal Hypersensitivity in Rodents |
| Q92255001 | Biomarkers of a Healthy Nordic Diet-From Dietary Exposure Biomarkers to Microbiota Signatures in the Metabolome |
| Q26777279 | Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders |
| Q38855986 | British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). |
| Q92246205 | Can Gut Microbiota Composition Predict Response to Dietary Treatments? |
| Q92925864 | Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome |
| Q37224309 | Comparison of faecal microbiota in Blastocystis-positive and Blastocystis-negative irritable bowel syndrome patients. |
| Q47864147 | Dietary therapies for functional bowel symptoms: Recent advances, challenges, and future directions |
| Q33616910 | Differential Effect of Sucrose and Fructose in Combination with a High Fat Diet on Intestinal Microbiota and Kidney Oxidative Stress. |
| Q54998518 | Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. |
| Q48305566 | Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome |
| Q92046631 | Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial |
| Q57059341 | Fecal microbiota transplantation for patients with irritable bowel syndrome: A meta-analysis protocol |
| Q38987853 | Food matters: how the microbiome and gut-brain interaction might impact the development and course of anorexia nervosa |
| Q38726443 | Food: The Main Course to Wellness and Illness in Patients With Irritable Bowel Syndrome |
| Q39376100 | From clinical uncertainties to precision medicine: the emerging role of the gut barrier and microbiome in small bowel functional diseases |
| Q47752088 | Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome |
| Q41770716 | Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease |
| Q36033672 | Geriatric Respondents and Non-Respondents to Probiotic Intervention Can be Differentiated by Inherent Gut Microbiome Composition |
| Q57472105 | Gluten and Functional Abdominal Pain Disorders in Children |
| Q41329575 | Gnotobiotic Human Colon Ex Vivo. |
| Q91962106 | Gut Microbiome: Profound Implications for Diet and Disease |
| Q47832545 | Gut Microbiota and the Neuroendocrine System |
| Q49985626 | Gut Microbiota-Based Therapies for Irritable Bowel Syndrome |
| Q26768550 | Gut microbiota role in irritable bowel syndrome: New therapeutic strategies |
| Q38676309 | Habitual diet and diet quality in Irritable Bowel Syndrome: A case-control study. |
| Q55190074 | Heat shock protein 70 protects mouse against post-infection irritable bowel syndrome via up-regulating intestinal γδ T cell's Th17 response. |
| Q49735833 | History, aims and present structure of psychosomatic medicine in Germany. |
| Q36144375 | IBS and IBD - separate entities or on a spectrum? |
| Q93017634 | Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS) |
| Q59798945 | Intestinal Microbiome in Irritable Bowel Syndrome before and after Gut-Directed Hypnotherapy |
| Q47773748 | Intestinal microbiome-gut-brain axis and irritable bowel syndrome. |
| Q39148827 | Irritable Bowel Syndrome and Stress-Related Psychiatric Co-morbidities: Focus on Early Life Stress |
| Q56965677 | Irritable bowel syndrome |
| Q55339881 | Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. |
| Q37538949 | Irritable bowel syndrome symptom severity improves equally with probiotic and placebo |
| Q38912505 | Irritable bowel syndrome, the microbiota and the gut-brain axis. |
| Q39018403 | Irritable bowel syndrome: a gut microbiota-related disorder? |
| Q26751193 | Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment |
| Q90603177 | Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis |
| Q38605779 | Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis |
| Q53364371 | Mechanistic understanding of the effects of probiotics in the modulation of abdominal pain: one study at a time. |
| Q37678008 | MetaDP: a comprehensive web server for disease prediction of 16S rRNA metagenomic datasets |
| Q35825753 | Microbial signatures in post-infectious irritable bowel syndrome--toward patient stratification for improved diagnostics and treatment |
| Q38811947 | Microbiome, antibiotics and irritable bowel syndrome |
| Q60955353 | Microbiota in the Gastrointestinal Tract |
| Q46302916 | Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome |
| Q38810529 | Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. |
| Q90228539 | Non-coeliac gluten sensitivity and the spectrum of gluten-related disorders: an updated overview |
| Q35657347 | Novel players in coeliac disease pathogenesis: role of the gut microbiota |
| Q42994335 | Nutrikinetic study of genistein metabolites in ovariectomized mice. |
| Q26772345 | Nutritional Keys for Intestinal Barrier Modulation |
| Q35853017 | On the origin of species: Factors shaping the establishment of infant's gut microbiota. |
| Q26765219 | Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? |
| Q39458419 | Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. |
| Q36002382 | Population-level analysis of gut microbiome variation |
| Q60929177 | Probiotics on Pediatric Functional Gastrointestinal Disorders |
| Q90178232 | Randomised clinical trial: effect of low-FODMAP rye bread versus regular rye bread on the intestinal microbiota of irritable bowel syndrome patients: association with individual symptom variation |
| Q34670890 | Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome |
| Q33465766 | Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome |
| Q26779200 | Selective Manipulation of the Gut Microbiota Improves Immune Status in Vertebrates |
| Q47096228 | Stress & the gut-brain axis: Regulation by the microbiome |
| Q48248882 | Sucrase-isomaltase 15Phe IBS risk variant in relation to dietary carbohydrates and faecal microbiota composition. |
| Q57167488 | The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders |
| Q59353836 | The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection |
| Q64259614 | The Impact of Low-FODMAPs, Gluten-Free, and Ketogenic Diets on Gut Microbiota Modulation in Pathological Conditions |
| Q37729859 | The Low FODMAP Diet: Many Question Marks for a Catchy Acronym |
| Q93332321 | The microbiome and ophthalmic disease |
| Q89718059 | The multicomponent medication Spascupreel attenuates stress-induced gut dysfunction in rats |
| Q64900045 | The role of diet in the prevention and treatment of Inflammatory Bowel Diseases. |
| Q47425661 | The stress concept in gastroenterology: from Selye to today |
| Q94093775 | UEG Week 2018 Poster Presentations |
| Q38515695 | Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome |
| Q50516321 | Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach. |
| Q93209587 | Volatomics in inflammatory bowel disease and irritable bowel syndrome |
| Q57794775 | uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea |
Search more.